HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help
Market News Market Pulse Stocks News ETF News Crypto News

Dianthus 7.3M share Secondary priced at $81.00

By TheFly | March 11, 2026, 6:05 AM
DNTH
+9.71%
Dianthus Therapeutics Inc

The deal size was increased to $625M in common stock from $400M in common stock. Jefferies, Evercore ISI, Stifel, Guggenheim and William Blair acted as joint book running managers for the offering.

Claim 70% Off TipRanks Premium

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Mentioned In This Article

DNTH
+9.71%
Dianthus Therapeutics Inc

Latest News

2 hours
Dianthus 7.3M share Secondary priced at $81.00 DNTH TipRanks
Mar-10
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering DNTH +9.71% GlobeNewswire
Mar-10
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) DNTH +9.71% Insider Monkey
Mar-09
Dianthus Therapeutics Has Appreciated 12-Fold Over Two Years. What's Going On? DNTH +21.52% Investor's Business Daily
Mar-09
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering DNTH +21.52% DNTH +9.71% GlobeNewswire
Mar-09
Dianthus Therapeutics Stock Rallies-Rare Disease Study Success Fuels Optimism DNTH +21.52% Benzinga
Mar-09
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates DNTH +21.52% Zacks
Mar-09
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results DNTH +21.52% GlobeNewswire
Mar-09
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) DNTH +21.52% GlobeNewswire
Mar-08
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) DNTH GlobeNewswire
Mar-05
Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? DNTH Zacks
Mar-04
Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates DNTH +11.99% Zacks
Mar-03
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DNTH GlobeNewswire
Feb-24
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference DNTH GlobeNewswire
Feb-13
Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans DNTH MarketBeat
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)